公开(公告)号：EP3143404B1

公开(公告)日：2018-08-29

申请号：EP15727150.3

申请日：2015-05-15

申请人： Amgen Inc.

发明人： GORSKI, Kevin ,  PARNES, Jane, R. ,  BIGLER, Jeanette ,  BOEDIGHEIMER, Michael, J. ,  WELCHER, Andrew, A.

IPC分类号： G01N33/533

CPC分类号： G01N33/505 ,  G01N33/533 ,  G01N33/582 ,  G01N2333/4715 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5437 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/52

摘要： The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.

公开(公告)号：EP3467501B1

公开(公告)日：2020-11-04

申请号：EP18190640.5

申请日：2015-05-15

申请人： Amgen Inc.

发明人： GORSKI, Kevin ,  PARNES, Jane, R. ,  BIGLER, Jeanette ,  BOEDIGHEIMER, Michael, J. ,  WELCHER, Andrew, A.

IPC分类号： G01N33/533

公开(公告)号：EP3143404A1

公开(公告)日：2017-03-22

申请号：EP15727150.3

申请日：2015-05-15

申请人： Amgen Inc.

发明人： GORSKI, Kevin ,  PARNES, Jane, R. ,  BIGLER, Jeanette ,  BOEDIGHEIMER, Michael, J. ,  WELCHER, Andrew, A.

IPC分类号： G01N33/533

CPC分类号： G01N33/505 ,  G01N33/533 ,  G01N33/582 ,  G01N2333/4715 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5437 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/52

摘要： The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.

摘要翻译： 本公开涉及一种用于检测受到具有免疫组分的疾病或病症影响的受试者中的T辅助细胞或CTL亚群的方法。 通过检测治疗或不利方向的T辅助细胞和CTL的倾斜来确定治疗疾病或病症的功效的方法也是有用的。

公开(公告)号：EP1238077A1

公开(公告)日：2002-09-11

申请号：EP00986374.7

申请日：2000-12-14

申请人： Amgen Inc.,

发明人： JING, Shuqian ,  WELCHER, Andrew, A. ,  FOX, Gary, M. ,  SHU, Junyan ,  BOEDIGHEIMER, Michael, J. ,  BENNETT, Brian, D.

IPC分类号： C12N15/12 ,  C12N15/62 ,  C12N5/10 ,  C07K14/705 ,  C07K16/28 ,  G01N33/50 ,  G01N33/566 ,  C12Q1/68 ,  A01K67/027 ,  A61K31/70 ,  A61K38/17 ,  A61K39/395

CPC分类号： G01N33/6893 ,  A01K2217/05 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00 ,  C07K14/70578 ,  C07K2319/00 ,  C12N2799/021 ,  G01N2333/525 ,  G01N2333/70578 ,  G01N2500/00

摘要： The present invention provides novel TNFr/OPG-like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies, and methods for producing TNFr/OPG-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases with TNFr/OPG-like polypeptides.

公开(公告)号：EP3467501A1

公开(公告)日：2019-04-10

申请号：EP18190640.5

申请日：2015-05-15

申请人： Amgen Inc.

发明人： GORSKI, Kevin ,  PARNES, Jane, R. ,  BIGLER, Jeanette ,  BOEDIGHEIMER, Michael, J. ,  WELCHER, Andrew, A.

IPC分类号： G01N33/533

摘要： The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.

公开(公告)号：EP1239870A1

公开(公告)日：2002-09-18

申请号：EP00982398.0

申请日：2000-12-04

申请人： Amgen Inc.,

发明人： CALZONE, Frank, J. ,  LUETHY, Roland ,  BOEDIGHEIMER, Michael, J. ,  ZHU, Jun ,  CHUNG, Young-ah ,  JING, Shuqian

IPC分类号： A61K38/20 ,  C07K14/47 ,  C07K16/24 ,  C12N15/25 ,  A01K67/027 ,  C12N15/62 ,  C12N5/10 ,  C12N5/12 ,  G01N33/53

CPC分类号： C07K14/54 ,  A61K38/00 ,  C07K2319/00 ,  C12N2799/021

摘要： The present invention provides novel Interleukin-1 Receptor Antagonist-Like (IL-1ra-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IL-1ra-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IL-1ra-L polypeptides.